Steven Finkbeiner,1,2,3 Ana Maria Cuervo,5 Richard I. Morimoto,6 and Paul J. Muchowski1,3,4 1Gladstone Institute of Neurological Disease and Departments of 2Physiology, 3Neurology, and 4Biochemistry and Biophysics, University of California, San Francisco, San Francisco, California 94158, 5Department of Anatomy and Structural Biology, Marion Bessin Liver Research Center, Albert Einstein College ...

Over the last two decades, patients have relied on the use of self-injectable disease modifying agents for the treatment of multiple sclerosis. The need for frequent injections has affected treatment up take and adherence. Fingolimod, the first oral disease modifying agent to be licensed in Europe and the United States, has been shown to be effective in reducing relapse rates in comparison to p...